Medicenna Bets on 'Superkine' Engineering to Outsmart Cancer and Costs

TORONTO, ON – June 26, 2026 – In the high-stakes world of clinical-stage biotechnology, progress is measured not just in scientific breakthroughs, but in the delicate dance between innovation and financial endurance. Medicenna Therapeutics finds itself squarely at this intersection, as revealed in its fiscal year 2026 report. The company is advancing a compelling pipeline of engineered immunotherapies aimed at cancers that have outsmarted current treatments, all while executing a financial strategy designed to keep the lights on long enough to reach critical, value-driving milestones.

For the curious professional, Medicenna presents a fascinating case study in modern drug development. It's a story of sophisticated protein engineering, strategic clinical bets, and the relentless pressure of the cash runway. The company’s latest update highlights promising anti-tumor activity in its lead programs, but also underscores the financial realities that govern its path forward. As President and CEO Dr. Fahar Merchant stated, the goal is to “provide better and safer options to patients where mega-blockbuster therapies have failed.” The question is how they navigate the path to get there.

MDNA11: A New Front Against Checkpoint Inhibitor Resistance

The centerpiece of Medicenna's clinical efforts is MDNA11, a next-generation 'Superkine' version of interleukin-2 (IL-2). For decades, IL-2 has been known as a potent immune stimulator, but its use has been hampered by severe toxicity and a non-specific mechanism that can inadvertently boost immunosuppressive cells. Medicenna's innovation is to re-engineer the molecule to preferentially bind to the receptors on cancer-killing T cells and Natural Killer (NK) cells, while avoiding the receptors on regulatory T cells (Tregs) that can dampen an anti-tumor response. The goal is to maximize the therapeutic effect while minimizing the collateral damage.

This engineering appears to be paying off. The company reports that in its Phase 1/2 ABILITY-1 study, MDNA11 is showing “compelling anti-tumor activity” in patients with advanced cancers who have already failed treatment with blockbuster checkpoint inhibitors like pembrolizumab. Data presented over the past year has pointed to response rates in the 30-40% range for patients with checkpoint-resistant melanoma and endometrial cancer—a significant signal in a patient population with few remaining options. This suggests MDNA11 could have a crucial role in overcoming one of the biggest challenges in modern oncology: treatment resistance.

The next six months will be pivotal. Medicenna expects to complete enrollment for the ABILITY-1 study in the third quarter of 2026, with key data readouts anticipated before year-end. These results will be instrumental in guiding the design of a potential registrational trial and, critically, in advancing partnership discussions. The company is not just waiting for monotherapy data; it's also exploring MDNA11 in combination with checkpoint inhibitors in earlier lines of therapy through the NEO-CYT trial, a move that could significantly broaden its market potential.

MDNA113: Designing a Smarter, Safer Bifunctional Weapon

While MDNA11 advances through the clinic, Medicenna is also developing what could be the next logical step in immunotherapy: MDNA113. This molecule is a first-in-class bifunctional 'Superkine' that fuses an anti-PD-1 antibody—the same mechanism used by drugs like Keytruda—directly to a tumor-targeted IL-2 Superkine. The design is elegant in its strategy: use the PD-1 binder to home in on the tumor microenvironment and then unleash the potent, localized power of the IL-2 Superkine to activate a powerful immune attack, right where it's needed most.

This approach of 'cis-binding' synergy is a hot area in oncology R&D, but Medicenna claims a key differentiator. Preclinical data presented at the 2026 AACR Annual Meeting showed MDNA113 to be safer even at doses 30-fold higher than a competing agent. This is a crucial claim. The history of IL-2 development is littered with programs that failed due to toxicity, a fate that befell Nektar Therapeutics' once-promising BEMPEG. By demonstrating a wider therapeutic window, MDNA113 could potentially be dosed more aggressively and effectively than its predecessors, a key factor for achieving deep and durable responses.

Medicenna is moving quickly to translate this preclinical promise into clinical reality. The company is advancing MDNA113 through IND-enabling studies with a target to file an Investigational New Drug (IND) application in the fourth quarter of 2026. This timeline places it on a path to enter first-in-human trials shortly thereafter, a critical step in validating its differentiated design.

The Biotech Balancing Act: Funding the Future

This ambitious pipeline development doesn't come cheap. Medicenna reported a net loss of $18.4 million for fiscal 2026, up from $11.8 million the previous year, largely driven by increased R&D expenses for its expanding clinical trials. The company ended the fiscal year with $6.3 million in cash.

Herein lies the classic biotech balancing act. Medicenna projects its cash runway will extend through the first quarter of calendar 2027, but this projection hinges on the successful completion of a “contemplated structured financing” with a firm named Sorbie. This dependency highlights the immense pressure clinical-stage companies face to secure funding to bridge the gap between promising data and the next major inflection point.

To navigate this complex environment, the company has made a shrewd strategic move by appointing Dr. Nageatte Ibrahim as fractional Chief Medical Officer. Dr. Ibrahim brings a wealth of experience from her long tenure at Merck, where she was involved in the clinical development of the very drug—pembrolizumab—that MDNA11 is being tested with. Her expertise in immunotherapy combinations and regulatory strategy is a significant addition, providing crucial guidance for the company's clinical programs and bolstering confidence for potential investors and partners.

Bizaxofusp: The Partnership Key

Rounding out Medicenna's strategic toolkit is bizaxofusp, a Phase 3-ready asset for recurrent glioblastoma (rGBM), one of the most aggressive and uniformly fatal forms of brain cancer. The drug, an engineered IL-4 Superkine, is administered directly into the brain tumor and has already shown promising survival data in a Phase 2b trial. With both FastTrack and Orphan Drug status from the FDA, bizaxofusp is a de-risked and attractive asset.

Medicenna is not planning to fund the costly Phase 3 trial itself. Instead, it is actively pursuing a partnership. A successful deal for bizaxofusp could provide a significant infusion of non-dilutive capital, dramatically altering the company's financial landscape. Such a partnership would not only fund the advancement of a potentially life-saving therapy for a desperate patient population but would also alleviate financial pressure on the MDNA11 and MDNA113 programs, allowing the company to negotiate future deals from a position of greater strength.